Head-To-Head Review: Swedish Orphan Biovitrum (OTCMKTS:BIOVF) vs. CareDx (NASDAQ:CDNA)
by Renee Jackson · The Cerbat GemCareDx (NASDAQ:CDNA – Get Free Report) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.
Valuation & Earnings
This table compares CareDx and Swedish Orphan Biovitrum”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CareDx | $458.09 million | 7.82 | -$21.35 million | $2.07 | 33.43 |
| Swedish Orphan Biovitrum | $2.89 billion | 5.28 | $48.85 million | $0.45 | 95.11 |
Swedish Orphan Biovitrum has higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for CareDx and Swedish Orphan Biovitrum, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CareDx | 0 | 5 | 3 | 0 | 2.38 |
| Swedish Orphan Biovitrum | 0 | 3 | 4 | 0 | 2.57 |
CareDx currently has a consensus price target of $57.00, indicating a potential downside of 17.63%. Given CareDx’s higher probable upside, analysts plainly believe CareDx is more favorable than Swedish Orphan Biovitrum.
Profitability
This table compares CareDx and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CareDx | 24.23% | 2.87% | 2.17% |
| Swedish Orphan Biovitrum | 4.74% | 17.72% | 9.27% |
Risk & Volatility
CareDx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
About CareDx
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.